Table 2 Treatment and outcome of patients
Lymphocyte differential count in BALF | |||
|---|---|---|---|
Variables | >15% (n = 24) | ≤15% (n = 13) | P value |
Treatment for CFIIP before admission | 5 (21.7%) | 5 (38.5%) | 0.69 |
corticosteroid | 2 (8.3%) | 1 (7.7%) | 1.00 |
corticosteroid + CyA | 1 (4.2%) | 2 (15.4%) | 0.28 |
pirfenidone | 2 (8.3%) | 1 (7.7%) | 1.00 |
Treatment for AE of CFIIP | |||
corticosteroid | 10 (41.7%) | 3 (23.1%) | 0.31 |
corticosteroid + CyA | 6 (25.0%) | 4 (30.8%) | 0.72 |
corticosteroid + CY | 0 (0.0%) | 3 (23.1%) | 0.04 |
corticosteroid + CyA + CY | 8 (33.3%) | 3 (23.1%) | 0.71 |
Outcome | |||
Mechanical ventilation | 4 (16.7%) | 5 (38.5%) | 0.23 |
90-day mortality | 4 (16.7%) | 8 (61.5%) | <0.01 |
Overall survival, months | 16.5 (5.4–25.8) | 1.7 (0.6–4.0) | <0.01 |
Death during observation period | 9 (37.5%) | 13 (100.0%) | <0.01 |